Details:
The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Lead Product(s): BI 456906
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Zealand Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021